First report of KPC variants conferring ceftazidime-avibactam resistance in Colombia: introducing KPC-197
Microbiology Spectrum · 2024
DOI: 10.1128/spectrum.04105-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, 2024. Verfasst von Elsa De la Cadena und 11 weiteren Autor:innen. Beteiligte Einrichtung: Grupo de Investigación en Resistencia Antimicrobiana y Epidemiología Hospitalaria, Universidad El Bosque, Bogotá, Colombia. Hauptthemen laut MEDLINE: Azabicyclo Compounds, Ceftazidime, Klebsiella pneumoniae, Drug Combinations. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Resistance to ceftazidime-avibactam (CZA) due to Klebsiella pneumoniae carbapenemase (KPC) variants is increasing worldwide. We characterized two CZA-resistant clinical Klebsiella pneumoniae strains by antimicrobial susceptibility test, conjugation assays, and WGS. Isolates belonged to ST258 and ST45, and produced a KPC-31 and a novel variant KPC-197, respectively. The novel KPC variant presents a deletion of two amino acids on the Ω-loop (del_168–169_EL) and an insertion of two amino acids in position 274 (Ins_274_DS). Continued surveillance of KPC variants conferring CZA resistance in Colombia is warranted. IMPORTANCE Latin America and the Caribbean is an endemic region for carbapenemases. Increasingly high rates of Klebsiella pneumoniae carbapenemase (KPC) have established ceftazidime-avibactam (CZA) as an essential antimicrobial for the treatment of infections due to MDR Gram-negative pathogens. Although other countries in the region have reported the emergence of CZA-resistant KPC variants, this is the first description of such enzymes in Colombia. This finding warrants active surveillance, as dissemination of these variants could have devastating public health consequences.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Grupo de Investigación en Resistencia Antimicrobiana y Epidemiología Hospitalaria, Universidad El Bosque, Bogotá, Colombia.
- Department of Molecular Biology and Microbiology, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
- CWRU-Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology (Case VA CARES), Cleveland, Ohio, USA.
- Research Service, VA Northeast Ohio Healthcare System, Cleveland, Ohio, USA.
- Fundación Hospital San Vicente de Paul, Rionegro, Colombia.
- Clínica Farallones Christus Sinergia, Cali, Colombia.
ORCID-Profile: Elsa De la Cadena, María Fernanda Mojica, Laura J Rojas, Natalia Restrepo, Robert A Bonomo
Zitieren
APA
De la Cadena, E., Mojica, M. F., Rojas, L. J., Castro, B. E., García-Betancur, J. C., Marshall, S. H., Restrepo, N., Castro-Caro, N. P., Fonseca-Carrillo, M., Pallares, C., Bonomo, R. A., & Villegas, M. V. (2024). First report of KPC variants conferring ceftazidime-avibactam resistance in Colombia: introducing KPC-197. Microbiology Spectrum. https://doi.org/10.1128/spectrum.04105-23
Vancouver
De la Cadena E, Mojica MF, Rojas LJ, Castro BE, García-Betancur JC, Marshall SH, et al. First report of KPC variants conferring ceftazidime-avibactam resistance in Colombia: introducing KPC-197. Microbiology Spectrum. 2024. doi:10.1128/spectrum.04105-23
BibTeX
@article{DelaCadena2024,
author = {De la Cadena, Elsa and Mojica, María Fernanda and Rojas, Laura J and Castro, Betsy E and García-Betancur, Juan Carlos and Marshall, Steven H and Restrepo, Natalia and Castro-Caro, Nancy Patricia and Fonseca-Carrillo, Magalis and Pallares, Christian and Bonomo, Robert A and Villegas, María Virginia},
title = {First report of KPC variants conferring ceftazidime-avibactam resistance in Colombia: introducing KPC-197},
journal = {Microbiology Spectrum},
year = {2024},
doi = {10.1128/spectrum.04105-23}
}
EUVIMED